Key facts
- This page summarizes Xinzhou Li's Form 4 filing for NovaBay Pharmaceuticals, Inc. (NBY).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 25 May 2021, 16:46.
Xinzhou Li - 21 May 2021 Form 4 Insider Report for NovaBay Pharmaceuticals, Inc. (NBY)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- NBY
- Reported as of
- 21 May 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/ Justin Hall as attorney in fact for Xinzhou Li
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Xinzhou Li filed Form 4 for NovaBay Pharmaceuticals, Inc. (NBY) on 25 May 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NBY
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +30,000
- Change %
- Price
- $0.000000
- Shares after
- 30,000
- Date
- 21 May 2021
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 30,000
- Exercise price
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on the one year anniversary of the date of grant.